tailieunhanh - Báo cáo y học: "More than just B-cell inhibitio"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: More than just B-cell inhibition. | Ruderman and Pope Arthritis Research Therapy 2011 13 125 http content 13 4 125 EDITORIAL L_ More than just B-cell inhibition Eric M Ruderman and Richard M Pope See related research by Chang etal. http content 13 4 R115 Abstract Despite tremendous advances in the therapy of rheumatoid arthritis RA there remains interest in oral agents that may offer benefits that are similar to or better than those of biologic therapies. In their paper Chang and colleagues demonstrate the effectiveness of a Bruton tyrosine kinase Btk inhibitor in two models of RA. Btk inhibition impacts several pathways affecting both B-cell and macrophage activation making it a promising target in RA. However other kinase inhibitors have failed to transition from animal models to human therapy so it remains to be seen whether a Btk inhibitor will have a role in the RA treatment armamentarium. Therapy for rheumatoid arthritis RA has advanced tremendously over the past 10 years. Biologic therapy employing recombinant antibodies and receptors has become the standard of care. Neutralization of cytokines tumor necrosis factor-alpha and interleukin-6 inhibition of co-stimulatory pathways CTLA4Ig and B-cell depletion anti-CD20 have all been shown to be effective therapies. However each requires parenteral administration is expensive and may result in undesired side effects. Over the last several years there have been intensified efforts to develop small-molecule inhibitors that can be taken orally and that may result in less expensive safer and more conveniently administered therapy. In this issue of Arthritis Research Therapy Chang and colleagues 1 present data demonstrating the effectiveness of a selective Bruton tyrosine kinase Btk inhibitor PCI-32765 in two experimental models of RA. Btk was originally identified as defective in patients who had X-linked agammaglobulinemia and who exhibited a profound reduction of B cells. Btk is a non-receptor .

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.